Overview

On July 21, 2005, Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB.I), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that it has completed the acquisition of Primus Corporation, a leader in the field of in vitro diagnostic testing for hemoglobin A1c and hemoglobin variants.

Significance

Trinity’s direct sales force and worldwide distribution network further expands Primus’ reach.

In addition to a new fast-growing and profitable business line, Trinity will also gain access to the new Primus Rapid Gel product which will compete in the US $100 million point-of-care A1c market and is based on the Company’s unique boronate affinity methodology.

Crosstree’s Role

Crosstree Capital Partners served as exclusive financial advisor to Primus Corporation.

Crosstree conducted a targeted global strategic sale process for Primus, bringing in an array of options and optimizing terms for the Company.